Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 5, 2007

BioVectra to Manufacture Helix’ Lung Cancer Candidate

  • Helix BioPharma signed an agreement with BioVectra to manufacture L-DOS47 bulk drug product for clinical testing in patients with adenocarcinoma of the lung. "BioVectra is a natural choice for our clinical manufacturing program requirements because in addition to their high calibre capabilities in the cGMP production of biopharmaceuticals, they are also one of the largest North American producers of the urease substance at the heart of our L-DOS47 drug product," notes John Docherty, Helix' vp of corporate development.

    During 2007, Helix intends to complete the remaining preclinical animal testing work with L-DOS47, in parallel with finalizing its clinical manufacturing activities.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »